IMAGINE THIS: Instead of going to an infusion center for treatment, you can switch to a weekly injection at home. That’s now a reality for many Alzheimer’s patients.
Caring for someone with Alzheimer’s is demanding enough. Now, instead of traveling for hours of infusions, families can turn to Leqembi IQLIK—a once-weekly injection approved by the FDA that makes treatment simpler, safer, and closer to home.
They’re not just pills—they’re precision infusions designed to slow Alzheimer’s at its source. See UCLA’s cutting-edge Amyloid Immunotherapy Care Program, and what it feels like to begin treatment with Leqembi (lecanemab) and Kisunla (donanemab).
Leqembi, the first Alzheimer’s-modifying drug, is a giant step forward—but how many people are getting it, and what does it really cost the average American? We dig into the numbers, the barriers, and the path forward.
FDA approves a newly recommended dosing schedule for Kisunla (Donanemab). It’s significantly safer due to lowered ARIA-E rates, which has been the main problem with these drugs.
Lecanemab (marketed as Leqembi) is today’s top Alzheimer’s drug. Why does equitable access to this drug remain a significant challenge? What needs to be done?
Lecanemab is today’s #1 Alzheimer’s antibody. (Brand name: Leqembi) Washington University researchers found Lecanemab’s adverse events to be rare and manageable in very mild or mild Alzheimer’s.
See how the class of weight loss and diabetes drugs that includes Ozempic and Wegovy have the added benefit of protecting against the development of dementia.
Alzheimer’s rates are on the rise. How is today’s best treatment, Leqembi (generic lecanemab) doing in the fight against it?
See why Leqembi is even more effective in males than females, at fighting Alzheimer’s.
VIDEO:
Understand dementia better. Get helpful insights and key facts.
DIET VIDEO + ARTICLE: Healthy? Normal blood sugar? No diabetes? Even so, find out how the more sugar you eat, the less memory you get.
ASTONISHING VIDEO & ARTICLE: Dementia-risk was tested for 17 sugar levels in 2000 people. Each higher level bumped up the risk, without exception. See why researchers found these results so compelling.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.
